Bominda Biotech Secures Tens of Millions in Pre-A Funding Led by Chongshan Capital to Advance Pet Disease Diagnostic Platform

VCBeat has learned that Nanjing Bominada Biotechnology Co., Ltd. (Bominada) has announced the completion of its tens-of-millions-yuan Pre-A financing round. The round was led by Chongshan Capital, with participation from Nanjing Jingyong, Shanghai Yueyin, and Guohua Health.

Bominda is a leader in the niche sector of pet health, entering the market through pet disease testing and covering the entire process of pet health management. The team brings together a group of professional, high-caliber management and technical talents: Founder Dr. Cheng Aiyang spent nearly 20 years in the United States, possessing extensive R&D experience in biochemistry and molecular biology, as well as laboratory management standards aligned with international practices; Co-founder Dr. Cao Jing has many years of management experience in hospitals and large multinational corporations, and is a senior operations expert in the field of medical products.

It is reported that BominDa is the only enterprise in China to have independently developed a canine allergen-specific IgE antibody detection product, holding two authorized national invention patents. The company offers nearly 100 testing items across six major categories—including molecular diagnostics, antimicrobial susceptibility testing, pathological examination, allergen screening, and genetic testing—along with various customized services. Serving nearly 1,000 clients, BominDa holds a leading position in the domestic industry.

Among these, products and services such as sample preservation solutions developed for the safe detection of zoonotic diseases, tests for pathogenic gene mutations associated with feline infectious peritonitis, and multiple feline genetic testing panels have filled numerous gaps in the domestic market. The company’s Luminex liquid bead array-based detection platform is one of the few clinical-grade testing platforms in China concurrently recognized by both the U.S. FDA and the China CFDA.

Recently, Bomingda upgraded its pathology testing center by introducing the Hamamatsu NanoZoomer-SQ digital slide scanner from Japan, enabling remote acquisition and observation of pathological slides and significantly improving testing efficiency. After becoming the first in China to offer uninterrupted seven-day-a-week testing services, Bomingda recently launched an online physician training and exchange platform as well as an online customer service system.

Dr. Cheng Aiyang stated that Bominda focuses on pet disease testing, establishing its core profit model by providing third-party testing services to veterinary hospitals and analyzing the resulting test data. Meanwhile, these testing services and data processing efforts positively impact various aspects of pet health, such as supplying epidemiological data for disease prevention and offering precise data support for treatment, thereby creating a closed-loop pet health ecosystem. Furthermore, third-party testing companies hold significant potential in the area of pet health check-ups.

Mass-market pet health checkups rely more heavily on high-quality, low-cost testing services. Specialized, large-scale, and highly efficient third-party testing laboratories can significantly reduce testing costs through technological advancements and optimized resource allocation. Collaboration between veterinary hospitals and third-party testing institutions can help realize the vision of “ensuring every pet receives proper care,” making affordable health screenings and vaccination services accessible to all pets.

Lu Dongcheng, Founding Executive Partner at Chongshan Capital, stated, “Driven by China’s rapid economic growth and demographic shifts such as the expanding middle class and rising single-person households, the Chinese pet healthcare market holds substantial growth potential. The market size is conservatively estimated to exceed RMB 100 billion in the future, with the pet diagnostics sector accounting for 10% of the total market share.”

“Compared to the relatively mature model in the United States, which relies heavily on third-party laboratories for pet disease testing, China’s third-party pet diagnostic testing industry still has significant room for growth. It is poised for explosive expansion over the next 5–10 years, with an even greater market potential in the pet health checkup sector. With strong technological capabilities, a competitive team, and first-mover advantages, BominDa has the potential to become a benchmark and leading enterprise in this field in China.”

Zhou Hai, Partner Representative of Nanjing Jingyong Medical & Health Venture Capital Fund, stated: “With its headquarters established in Nanjing, Bomingda can fully leverage local government resources and geographic advantages to better penetrate the Yangtze River Delta market. The company has chosen to focus on the field of pet disease diagnostics, which is still in its early stages in China, demonstrating forward-thinking strategic planning. Additionally, the company boasts strong R&D capabilities, maintains steady and solid growth, and has a business model that has been validated by the market. Therefore, we are optimistic about the company’s future development prospects.”

According to VCBeat,The funds from this round of financing will be primarily used for the continued research and development, as well as the promotion, of third-party testing products.With the support of capital, Bominda will take a new step toward its goal of becoming a leading professional animal healthcare service provider in China.

Chongshan Capital is an investment fund focused on the healthcare and wellness sector. Its management team comprises seasoned industry professionals with robust capabilities in resource integration and post-investment management. The firm is dedicated to identifying and nurturing China’s most outstanding and high-growth healthcare startups and enterprises, driving the development and transformation of the healthcare industry through a model that integrates industrial expertise with capital.

Nanjing Jingyong is a specialized healthcare fund that focuses on niche sectors such as innovative drugs, mid-to-high-end medical devices, and specialized medical services. The fund’s management team comprises experts in healthcare and venture capital, while its advisory team includes recipients of China’s “Thousand Talents Plan” in the pharmaceutical sector and senior clinical specialists. Additionally, the fund has established an innovation and technology transfer platform in collaboration with professional institutions such as Nanjing Medical University and Nanjing Tech University.